178 related articles for article (PubMed ID: 31653812)
1. Contemporary assessment of extent of resection in molecularly defined categories of diffuse low-grade glioma: a volumetric analysis.
Kavouridis VK; Boaro A; Dorr J; Cho EY; Iorgulescu JB; Reardon DA; Arnaout O; Smith TR
J Neurosurg; 2019 Oct; 133(5):1291-1301. PubMed ID: 31653812
[TBL] [Abstract][Full Text] [Related]
2. Surgical, functional, and oncological considerations regarding awake resection for giant diffuse lower-grade glioma of more than 100 cm3.
Sauvageot S; Boetto J; Duffau H
J Neurosurg; 2023 Oct; 139(4):934-943. PubMed ID: 36964732
[TBL] [Abstract][Full Text] [Related]
3. The Role of Surgery in IDH-Wild-Type Lower-Grade Gliomas: Threshold at a High Extent of Resection Should be Pursued.
Wang P; Luo C; Hong PJ; Rui WT; Wu S
Neurosurgery; 2021 May; 88(6):1136-1144. PubMed ID: 33647953
[TBL] [Abstract][Full Text] [Related]
4. Rethinking extent of resection of contrast-enhancing and non-enhancing tumor: different survival impacts on adult-type diffuse gliomas in 2021 World Health Organization classification.
Park YW; Kim S; Han K; Ahn SS; Moon JH; Kim EH; Kim J; Kang SG; Kim SH; Lee SK; Chang JH
Eur Radiol; 2024 Feb; 34(2):1376-1387. PubMed ID: 37608093
[TBL] [Abstract][Full Text] [Related]
5. Proposed therapeutic strategy for adult low-grade glioma based on aggressive tumor resection.
Nitta M; Muragaki Y; Maruyama T; Ikuta S; Komori T; Maebayashi K; Iseki H; Tamura M; Saito T; Okamoto S; Chernov M; Hayashi M; Okada Y
Neurosurg Focus; 2015 Jan; 38(1):E7. PubMed ID: 25599276
[TBL] [Abstract][Full Text] [Related]
6. The Role of Extent of Resection in IDH1 Wild-Type or Mutant Low-Grade Gliomas.
Patel T; Bander ED; Venn RA; Powell T; Cederquist GY; Schaefer PM; Puchi LA; Akhmerov A; Ogilvie S; Reiner AS; Moussazadeh N; Tabar V
Neurosurgery; 2018 Jun; 82(6):808-814. PubMed ID: 28945860
[TBL] [Abstract][Full Text] [Related]
7. To treat or not to treat? A retrospective multicenter assessment of survival in patients with IDH-mutant low-grade glioma based on adjuvant treatment.
Paľa A; Coburger J; Scherer M; Ahmeti H; Roder C; Gessler F; Jungk C; Scheuerle A; Senft C; Tatagiba M; Synowitz M; Wirtz CR; Schmitz B; Unterberg AW
J Neurosurg; 2019 Jul; 133(2):273-280. PubMed ID: 31323633
[TBL] [Abstract][Full Text] [Related]
8. Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade Glioma.
Hervey-Jumper SL; Zhang Y; Phillips JJ; Morshed RA; Young JS; McCoy L; Lafontaine M; Luks T; Ammanuel S; Kakaizada S; Egladyous A; Gogos A; Villanueva-Meyer J; Shai A; Warrier G; Rice T; Crane J; Wrensch M; Wiencke JK; Daras M; Oberheim Bush NA; Taylor JW; Butowski N; Clarke J; Chang S; Chang E; Aghi M; Theodosopoulos P; McDermott M; Jakola AS; Kavouridis VK; Nawabi N; Solheim O; Smith T; Berger MS; Molinaro AM
J Clin Oncol; 2023 Apr; 41(11):2029-2042. PubMed ID: 36599113
[TBL] [Abstract][Full Text] [Related]
9. Molecular features and clinical outcomes in surgically treated low-grade diffuse gliomas in patients over the age of 60.
Morshed RA; Han SJ; Hervey-Jumper SL; Pekmezci M; Troncon I; Chang SM; Butowski NA; Berger MS
J Neurooncol; 2019 Jan; 141(2):383-391. PubMed ID: 30498891
[TBL] [Abstract][Full Text] [Related]
10. Impact of the extent of resection on the survival of patients with grade II and III gliomas using awake brain mapping.
Motomura K; Chalise L; Ohka F; Aoki K; Tanahashi K; Hirano M; Nishikawa T; Yamaguchi J; Shimizu H; Wakabayashi T; Saito R
J Neurooncol; 2021 Jun; 153(2):361-372. PubMed ID: 34009509
[TBL] [Abstract][Full Text] [Related]
11. Association of supratotal resection with progression-free survival, malignant transformation, and overall survival in lower-grade gliomas.
Rossi M; Gay L; Ambrogi F; Conti Nibali M; Sciortino T; Puglisi G; Leonetti A; Mocellini C; Caroli M; Cordera S; Simonelli M; Pessina F; Navarria P; Pace A; Soffietti R; Rudà R; Riva M; Bello L
Neuro Oncol; 2021 May; 23(5):812-826. PubMed ID: 33049063
[TBL] [Abstract][Full Text] [Related]
12. Updated therapeutic strategy for adult low-grade glioma stratified by resection and tumor subtype.
Nitta M; Muragaki Y; Maruyama T; Iseki H; Ikuta S; Konishi Y; Saito T; Tamura M; Chernov M; Watanabe A; Okamoto S; Maebayashi K; Mitsuhashi N; Okada Y
Neurol Med Chir (Tokyo); 2013; 53(7):447-54. PubMed ID: 23883555
[TBL] [Abstract][Full Text] [Related]
13. Surgery for Diffuse WHO Grade II Gliomas: Volumetric Analysis of a Multicenter Retrospective Cohort From the German Study Group for Intraoperative Magnetic Resonance Imaging.
Scherer M; Ahmeti H; Roder C; Gessler F; Jungk C; Pala A; Mayer B; Senft C; Tatagiba M; Synowitz M; Wirtz CR; Unterberg AW; Coburger J
Neurosurgery; 2020 Jan; 86(1):E64-E74. PubMed ID: 31574147
[TBL] [Abstract][Full Text] [Related]
14. National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States.
Ostrom QT; Shoaf ML; Cioffi G; Waite K; Kruchko C; Wen PY; Brat DJ; Barnholtz-Sloan JS; Iorgulescu JB
Neuro Oncol; 2023 Apr; 25(4):799-807. PubMed ID: 35994777
[TBL] [Abstract][Full Text] [Related]
15. Extent of resection and molecular pathologic subtype are potent prognostic factors of adult WHO grade II glioma.
Choi J; Kim SH; Ahn SS; Choi HJ; Yoon HI; Cho JH; Roh TH; Kang SG; Chang JH; Suh CO
Sci Rep; 2020 Feb; 10(1):2086. PubMed ID: 32034238
[TBL] [Abstract][Full Text] [Related]
16. Threshold of the extent of resection for WHO Grade III gliomas: retrospective volumetric analysis of 122 cases using intraoperative MRI.
Fujii Y; Muragaki Y; Maruyama T; Nitta M; Saito T; Ikuta S; Iseki H; Hongo K; Kawamata T
J Neurosurg; 2018 Jul; 129(1):1-9. PubMed ID: 28885120
[TBL] [Abstract][Full Text] [Related]
17. The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis.
Wijnenga MMJ; French PJ; Dubbink HJ; Dinjens WNM; Atmodimedjo PN; Kros JM; Smits M; Gahrmann R; Rutten GJ; Verheul JB; Fleischeuer R; Dirven CMF; Vincent AJPE; van den Bent MJ
Neuro Oncol; 2018 Jan; 20(1):103-112. PubMed ID: 29016833
[TBL] [Abstract][Full Text] [Related]
18. Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy.
Anand S; Chatterjee A; Gupta T; Panda P; Moiyadi A; Epari S; Patil V; Krishnatry R; Goda JS; Jalali R
World Neurosurg; 2021 Oct; 154():e176-e184. PubMed ID: 34245877
[TBL] [Abstract][Full Text] [Related]
19. Intraoperative 3D ultrasound-guided resection of diffuse low-grade gliomas: radiological and clinical results.
Bø HK; Solheim O; Kvistad KA; Berntsen EM; Torp SH; Skjulsvik AJ; Reinertsen I; Iversen DH; Unsgård G; Jakola AS
J Neurosurg; 2019 Feb; 132(2):518-529. PubMed ID: 30717057
[TBL] [Abstract][Full Text] [Related]
20. Risk Factors for Progression Among Low-Grade Gliomas After Gross Total Resection and Initial Observation in the Molecular Era.
Tom MC; Varra V; Leyrer CM; Park DY; Chao ST; Yu JS; Suh JH; Reddy CA; Balagamwala EH; Broughman JR; Kotagal KA; Vogelbaum MA; Barnett GH; Ahluwalia MS; Peereboom DM; Prayson RA; Stevens GHJ; Murphy ES
Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1099-1105. PubMed ID: 31022510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
